Ras inhibitors
AssigneeRevolution Medicines, Inc.
InventorsAdrian L. Gill, James Cregg, Elena S. Koltun, Yang Liu
Life of this patent
Estimating the term…
Abstract
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Claims8
A method of treating lung cancer in a subject in need thereof, wherein the lung cancer comprises a K-Ras G12C mutation, the method comprising administering to the subject a therapeutically effective amount of a compound having the following structure:
- or a pharmaceutically acceptable salt thereof.
A method of treating non-small cell lung cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound having the following structure:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.